Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors.

Muraoka-Cook RS, Kurokawa H, Koh Y, Forbes JT, Roebuck LR, Barcellos-Hoff MH, Moody SE, Chodosh LA, Arteaga CL.

Cancer Res. 2004 Dec 15;64(24):9002-11.

2.

Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1.

Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, Moses HL, Arteaga CL.

Mol Cell Biol. 2003 Dec;23(23):8691-703.

3.

Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.

Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL.

J Clin Invest. 2002 Jun;109(12):1551-9.

4.

ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells.

Muraoka RS, Lenferink AE, Law B, Hamilton E, Brantley DM, Roebuck LR, Arteaga CL.

Mol Cell Biol. 2002 Apr;22(7):2204-19.

5.

Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function.

Muraoka RS, Lenferink AE, Simpson J, Brantley DM, Roebuck LR, Yakes FM, Arteaga CL.

J Cell Biol. 2001 May 28;153(5):917-32.

Supplemental Content

Loading ...
Support Center